Jessica Chubak, PhD, is an epidemiologist who works to improve cancer diagnosis, treatment, control, and survivorship. Dr. Chubak’s methodological research focuses on the use of administrative and electronic health record data in epidemiologic and health services studies.
Dr. Chubak joined KPWHRI in 2007, bringing expertise in epidemiologic methods, pharmacoepidemiology, and cancer. Awarded a Fulbright graduate student grant, she pursued her master's degree in bioethics and health law in New Zealand before completing her PhD in Epidemiology at the University of Washington (UW). Dr. Chubak is an affiliate professor in the Department of Epidemiology at the UW School of Public Health, where she enjoys teaching and working with students.
Epidemiology; colorectal cancer; medication use; survivorship; recurrence; secondary prevention; quality of life; automated data collection; screening; animal-assisted activities; survivorship
Screening
Cancer risk and use of common medications
Mayer SE, Weiss NS, Chubak J, Doody DR, Carlson CS, Makar KW, Wurscher MA, Malone KE CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy 2019 Jan;30(2):187-193. doi: 10.1007/s10552-018-1117-x. Epub 2019-01-17. PubMed
Chubak J, McLerran D, Zheng Y, Singal AG, Corley DA, Doria-Rose VP, Doubeni CA, Kamineni A, Haas JS, Halm EA, Skinner CS, Zauber AG, Wernli KJ, Beaber EF, PROSPR consortium Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems 2019 Jan;28(1):91-98. doi: 10.1158/1055-9965.EPI-18-0452. Epub 2018-11-20. PubMed
Reed SC, Walker R, Ziebell R, Rabin B, Nutt S, Chubak J, Nekhlyudov L Cancer Survivors' Reported Discussions with Health Care Providers About Follow-Up Care and Receipt of Written Care Plans 2018 Dec;33(6):1181-1188. doi: 10.1007/s13187-017-1228-1. PubMed
Selby K, Jensen CD, Lee JK, Doubeni CA, Schottinger JE, Zhao WK, Chubak J, Halm E, Ghai NR, Contreras R, Skinner C, Kamineni A, Levin TR, Corley DA Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study 2018 Nov;169(7):439-447. doi: 10.7326/M18-0244. Epub 2018-09-18. PubMed
Chubak J, Yu O, Ziebell RA, Bowles EJA, Sterrett AT, Fujii MM, Boggs JM, Burnett-Hartman AN, Boudreau DM, Chen L, Floyd JS, Ritzwoller DP, Hubbard RA Risk of colon cancer recurrence in relation to diabetes 2018 Nov;29(11):1093-1103. doi: 10.1007/s10552-018-1083-3. Epub 2018-09-22. PubMed
Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose PV, Quinn VP, Jensen CD, Chubak J, Tiro J, Doubeni CA, Ghai NR, Skinner CS, Wernli K, Halm EA Patterns and predictors or repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States 2018 May;113(5):746-754. doi: 10.1038/s41395-018-0023-x. Epub 2018-02-27. PubMed
Jones SMW, Walker R, Fujii M, Nekhlyudov L, Rabin BA, Chubak J Financial difficulty, worry about affording care, and benefit finding in long-term survivors of cancer 2018 Apr;27(4):1320-1326. doi: 10.1002/pon.4677. Epub 2018-03-08. PubMed
The findings can help guide colorectal cancer screening decisions later in life.
Understanding emergency department use among adolescent and young adult cancer survivors can help address care gaps.
How KPWHRI is contributing to better cancer screening and better outcomes for patients.